home / stock / mpsyy / mpsyy quote
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $27.93 |
High: | $N/A |
Low: | $N/A |
Volume: | 9 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $N/A | $27.93 | $N/A | $N/A | 9 | 05-22-2018 |
$ | $27.93 | $27.93 | $27.93 | $27.93 | 141 | 05-21-2018 |
$ | $26.05 | $27.69 | $27.69 | $26.05 | 1,119 | 05-18-2018 |
$ | $N/A | $26.25 | $N/A | $N/A | 40 | 05-17-2018 |
$ | $26.25 | $26.25 | $26.25 | $26.25 | 1,023 | 05-16-2018 |
$ | $N/A | $26.39 | $N/A | $N/A | 59 | 05-15-2018 |
$ | $26.39 | $26.39 | $26.39 | $26.39 | 405 | 05-14-2018 |
$ | $N/A | $26.63 | $N/A | $N/A | 37 | 05-11-2018 |
$ | $N/A | $26.63 | $N/A | $N/A | 29 | 05-10-2018 |
$ | $N/A | $26.63 | $N/A | $N/A | 108 | 05-09-2018 |
$ | $26.63 | $26.63 | $26.63 | $26.63 | 233 | 05-08-2018 |
$ | $N/A | $27.12 | $N/A | $N/A | 67 | 05-07-2018 |
$ | $N/A | $27.12 | $N/A | $N/A | 12 | 05-04-2018 |
$ | $26.10 | $27.12 | $27.12 | $26.10 | 2,000 | 05-03-2018 |
$ | $N/A | $25.18 | $N/A | $N/A | 27 | 05-02-2018 |
$ | $N/A | $25.18 | $N/A | $N/A | 22 | 05-01-2018 |
$ | $N/A | $25.18 | $N/A | $N/A | 141 | 04-30-2018 |
$ | $N/A | $25.18 | $N/A | $N/A | 70 | 04-27-2018 |
$ | $25.35 | $25.18 | $25.55 | $25.18 | 524 | 04-26-2018 |
$ | $N/A | $26.385 | $N/A | $N/A | 15 | 04-25-2018 |
News, Short Squeeze, Breakout and More Instantly...
Morphosys Ag Sp/Adr Company Name:
MPSYY Stock Symbol:
OTCMKTS Market:
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 24, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer (CEO). The appointment will take effec...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 22, 2019 / MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019. MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today p...
Conference call and webcast (in English) to be held on May 8, 2019 at 2:00pm CEST (1:00pm BST/8:00am EDT) - MOR208: Rolling submission of L-MIND study data to FDA to support potential approval in the U.S. on track - David Trexler hired as President, MorphoSys US Inc.; build-up of c...